Long-term Cost-effectiveness of Various Initial Monotherapies for Mild to Moderate Hypertension

JAMA: The Journal of the American Medical Association

Volumn 263, Issue 3, 1990, Pages 407-413

  Edelson, Jonathan T ^a,c   Weinstein, Milton C ^b   Tosteson, Anna N A ^a   Williams, Larry ^a   Lee, Thomas H ^a   Goldman, Lee ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of Health Policy and Management Harvard School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; HYDROCHLOROTHIAZIDE; NIFEDIPINE; PRAZOSIN; PROPRANOLOL;

ARTICLE; COST; ECONOMIC ASPECT; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHOLESTEROL; COST-BENEFIT ANALYSIS; HUMAN; HYPERTENSION; META-ANALYSIS; MIDDLE AGE; PROPRANOLOL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025020597     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1990.03440030094028     Document Type: Article

References (47)

1. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41-63.
2. Pauly MV. The changing health care environment. Am J Med. 1986;81(6C):38.
3. Pauly MV, Stason WB. Contemporary considerations in the treatment of hypertension: cost, efficacy, preference. Am J Med. 1986;81(6C):1-2.
4. Gallup G, Cotugno HE. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med. 1986;81(6C):20-24.
5. Stason WB. Opportunities for improving the cost-effectiveness of anti-hypertensive treatment. Am J Med. 1986;81(6C):45-49.
6. Dzau VJ. Evolution of the clinical management of hypertension. Am J Med. 1987;82(1A):36-43.
7. Ray WA, Schaffner W, Oates JA. Therapeutic choice in the treatment of hypertension. Am J Med. 1986;81(6C):9-16.
8. Moser M. ‘Cost containment’ in the management of hypertension. Ann Intern Med. 1987;107:107-109.
9. Prichard BNC, Owens CWI. The management of hypertension. Br J Clin Pharmacol. 1986;21(suppl 2):129s-142s.
10. Weinberger MH. Treatment of hypertension in the 1990‘s. Am J Med. 1987;82(1A):44-49.
11. Gifford RW. Essential hypertension: cost-effective evaluation and treatment. Am J Med. 1986;81(6C):33-38.
12. 1988 Joint National Committee. The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1988;148:1023-1038.
13. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10:101-129.
14. Cardinale VA, ed. Red Book Drug Topics. Oradell, NJ: Medical Economics Books; 1987.
15. Kosman ME. Management of potassium problems during long-term diuretic therapy. JAMA. 1974;230:743-748.
16. Weinstein MC, Stason WB, Blumenthal D, McNeil BJ, Nichols AL, Shepard DS. Hypertension: A Policy Perspective. Cambridge, Mass: Harvard University Press; 1976.
17. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med. 1977;296:732-739.
18. Epstein AM, Begg CB, McNeil BJ. The effects of group size on test ordering for hypertensive patients. N Engl J Med. 1983;309:464-468.
19. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417-1426.
20. Consumer Price Index. Washington, DC: US Dept of Labor, Bureau of Statistics; 1971-1986. Detail reports.
21. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia, Pa: WB Saunders Co; 1980.
22. Duncan RC, Knapp RG, Miller MC. Introductory Biostatistics for the Health Sciences. New York, NY: John Wiley & Sons Inc; 1983.
23. Freis ED. The cardiovascular risks of thiazide diuretics. Clin Pharmacol Ther. 1986;39:239-244.
24. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on quality of life. N Engl J Med. 1986;314:1657-1664.
25. Kannel WB, Gordon T, McGee D. Diuretics and serum cholesterol. Lancet. 1977;1:1361-1362.
26. Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants. Am J Prev Med. 1986;2:248-255.
27. Amery A, Birkenhager W, Bulpitt C, et al. Influence of anti-hypertensive therapy on serum cholesterol in elderly hypertensive patients. Acta Cardiol. 1982;37:235-244.
28. Cutler JA, Furberg CD. Drug treatment trials in hypertension: a review. Prev Med. 1985;14:499-518.
29. Moser M. Treating hypertension: a review of clinical trials. Am J Med. 1986;81(6C):25-32.
30. Dollery CT. Risk factors, risk indicators, and benefit factors in hypertension. Am J Med. 1987;82(1A):2-8.
31. Hebert PR, Fiebach NH, Eberlein KA, Taylor JO, Hennekens CH. The community based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol. 1988;127:581-590.
32. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. JAMA. 1988;259:1976-1982.
33. Shea S, Cook EF, Kannel WB, Goldman L. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study. Circulation. 1985;71:22-30.
34. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J. 1985;291:97-104.
35. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3:379-392.
36. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:S61-S72.
37. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. β-Blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA. 1989;261:2087-2094.
38. Kaplan NM. Antihypertensive drugs: how different classes can impact patients’ coronary heart disease risk profile and quality of life. Am J Med. 1987;82(1A):9-14.
39. Williams GH. Quality of life and its impact on hypertensive patients. Am J Med. 1987;82:98-105.
40. Gengo FM, Fagan SC, de Padova A, Miller JK, Kinkel PR. The effect of β-blockers on mental performance on older hypertensive patients. Arch Intern Med. 1988;148:779-784.
41. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual symptoms in hypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med. 1988;148:788-794.
42. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.
43. Paperchase. Boston, Mass: Center for Clinical Computing, Beth Israel Hospital; 1988.
44. McMahon FG. Management of Essential Hypertension. 2nd ed. Mount Kisco, NY: Futura Publishing Co; 1984.
45. Frishman WH, ed. Clinical Pharmacology of Beta-adrenoreceptor Blocking Drugs. 2nd ed. East Norwalk, Conn: Appleton-Century-Crofts; 1984.
46. Schweitzer W, ed. Beta-blockers: Present Status and Future Prospects. Baltimore, Md: University Park Press; 1974.
47. Saxena PR, Forsyth RP, eds. Beta-adrenoreceptor Blocking Agents. New York, NY: American Elsevier Publishing Co; 1976.